These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 24368175)

  • 1. Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how.
    Hornberg JJ; Laursen M; Brenden N; Persson M; Thougaard AV; Toft DB; Mow T
    Drug Discov Today; 2014 Aug; 19(8):1131-6. PubMed ID: 24368175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies.
    Hornberg JJ; Laursen M; Brenden N; Persson M; Thougaard AV; Toft DB; Mow T
    Drug Discov Today; 2014 Aug; 19(8):1137-44. PubMed ID: 24374152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploratory drug safety: a discovery strategy to reduce attrition in development.
    Bass AS; Cartwright ME; Mahon C; Morrison R; Snyder R; McNamara P; Bradley P; Zhou YY; Hunter J
    J Pharmacol Toxicol Methods; 2009; 60(1):69-78. PubMed ID: 19422924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
    Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
    Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety biomarkers in preclinical development: translational potential.
    Sasseville VG; Mansfield KG; Brees DJ
    Vet Pathol; 2014 Jan; 51(1):281-91. PubMed ID: 24091814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonclinical Safety and Toxicology.
    Stark C; Steger-Hartmann T
    Handb Exp Pharmacol; 2016; 232():261-83. PubMed ID: 26489827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addressing toxicity risk when designing and selecting compounds in early drug discovery.
    Segall MD; Barber C
    Drug Discov Today; 2014 May; 19(5):688-93. PubMed ID: 24451294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicology in the drug discovery and development process.
    Dorato MA; Buckley LA
    Curr Protoc Pharmacol; 2006 Apr; Chapter 10():Unit10.3. PubMed ID: 22294168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies.
    Chapman K; Chivers S; Gliddon D; Mitchell D; Robinson S; Sangster T; Sparrow S; Spooner N; Wilson A
    Drug Discov Today; 2014 May; 19(5):528-32. PubMed ID: 24448068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The application of 3D cell models to support drug safety assessment: opportunities & challenges.
    Roth A; Singer T
    Adv Drug Deliv Rev; 2014 Apr; 69-70():179-89. PubMed ID: 24378580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/2nd communication: promising strategies].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(6):307-13. PubMed ID: 15282874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments.
    McGivern JV; Ebert AD
    Adv Drug Deliv Rev; 2014 Apr; 69-70():170-8. PubMed ID: 24309014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project.
    Verbist B; Klambauer G; Vervoort L; Talloen W; ; Shkedy Z; Thas O; Bender A; Göhlmann HW; Hochreiter S
    Drug Discov Today; 2015 May; 20(5):505-13. PubMed ID: 25582842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond profiling: using ADMET models to guide decisions.
    Segall M; Champness E; Obrezanova O; Leeding C
    Chem Biodivers; 2009 Nov; 6(11):2144-51. PubMed ID: 19937845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society.
    Bass AS; Vargas HM; Valentin JP; Kinter LB; Hammond T; Wallis R; Siegl PK; Yamamoto K
    J Pharmacol Toxicol Methods; 2011; 64(1):7-15. PubMed ID: 21689769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
    Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
    J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug discovery through stem cell-based organoid models.
    Ranga A; Gjorevski N; Lutolf MP
    Adv Drug Deliv Rev; 2014 Apr; 69-70():19-28. PubMed ID: 24582599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.